DZ2407A1 - Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant - Google Patents

Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant

Info

Publication number: DZ2407A1
Authority: DZ; Algeria
Prior art keywords: preparation; pharmaceutical compositions; compositions containing; sulfonylurea derivatives; derivatives process
Prior art date: 1997-01-29

Application number

DZ980017A

Other languages

English (en)

Inventor

Mark Anthony Dombroski

James Frederick Eggler

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-29

Filing date

1998-01-27

Publication date

2003-01-04

1998-01-27 Application filed by Pfizer filed Critical Pfizer

2003-01-04 Application granted granted Critical

2003-01-04 Publication of DZ2407A1 publication Critical patent/DZ2407A1/fr

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

DZ980017A 1997-01-29 1998-01-27 Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant DZ2407A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US3697997P	1997-01-29	1997-01-29

Publications (1)

Publication Number	Publication Date
DZ2407A1 true DZ2407A1 (fr)	2003-01-04

Family

ID=21891776

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ980017A DZ2407A1 (fr)	1997-01-29	1998-01-27	Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant

Country Status (40)

Country	Link
US (2)	US6166064A (fr)
EP (1)	EP0964849B1 (fr)
JP (1)	JP3573757B2 (fr)
KR (1)	KR100324058B1 (fr)
CN (1)	CN1127479C (fr)
AP (1)	AP929A (fr)
AR (1)	AR011093A1 (fr)
AT (2)	ATE242208T1 (fr)
AU (1)	AU723895B2 (fr)
BG (1)	BG103597A (fr)
BR (1)	BR9714328A (fr)
CA (1)	CA2279186C (fr)
CO (1)	CO4920230A1 (fr)
CZ (1)	CZ293173B6 (fr)
DE (2)	DE69722663T2 (fr)
DK (2)	DK1270565T3 (fr)
DZ (1)	DZ2407A1 (fr)
EA (1)	EA001803B1 (fr)
ES (2)	ES2198598T3 (fr)
HR (1)	HRP980045B1 (fr)
HU (1)	HUP0000567A3 (fr)
ID (1)	ID22223A (fr)
IL (1)	IL130855A0 (fr)
IS (1)	IS5099A (fr)
MA (1)	MA26468A1 (fr)
NO (1)	NO313279B1 (fr)
NZ (1)	NZ336248A (fr)
OA (1)	OA11079A (fr)
PA (1)	PA8444701A1 (fr)
PE (1)	PE57898A1 (fr)
PL (1)	PL335052A1 (fr)
PT (2)	PT964849E (fr)
SK (1)	SK283679B6 (fr)
TN (1)	TNSN98017A1 (fr)
TR (1)	TR199901816T2 (fr)
TW (1)	TW515788B (fr)
UY (1)	UY24861A1 (fr)
WO (1)	WO1998032733A1 (fr)
YU (1)	YU33799A (fr)
ZA (1)	ZA98685B (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6022984A (en) *	1998-07-27	2000-02-08	Pfizer Inc.	Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
EP1526383A3 (fr) *	1998-08-31	2005-11-16	Pfizer Products Inc.	Protéines de liaison pour diarylsulfonylurée
IT1303249B1 (it) *	1998-10-23	2000-11-06	Dompe Spa	Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
BR0014003A (pt) *	1999-09-14	2002-05-21	Pfizer Prod Inc	Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
US6808902B1 (en)	1999-11-12	2004-10-26	Amgen Inc.	Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2369967A1 (fr) *	2001-02-12	2002-08-12	Joseph Anthony Cornicelli	Methodes de traitement de maladies et de troubles relies au facteur nucleaire-kappa b
CN103232539B (zh)	2001-06-26	2015-06-03	安姆根弗里蒙特公司	抗opgl抗体
CA2459454A1 (fr)	2001-09-14	2003-03-27	Bayer Pharmaceuticals Corporation	Derives de benzofurane et de dihydrobenzofurane utiles comme agonistes du beta-3 adrenorecepteur
BR0214810A (pt) *	2001-11-30	2004-11-03	Pfizer Prod Inc	Combinação de um inibidor de il-1/18 com um inibidor de tnf para o tratamento de inflamação
US20030131370A1 (en) *	2001-12-14	2003-07-10	Pfizer Inc.	Disruption of the glutathione S-transferase-Omega-1 gene
EP1534282B1 (fr)	2002-07-09	2006-12-27	Boehringer Ingelheim Pharma GmbH & Co.KG	Compositions pharmaceutiques comprenant des agents anticholinergiques etinhibiteurs de p38 kinase pour le traitement des maladies respiratoires
EP2277543B1 (fr)	2002-09-06	2015-12-16	Amgen, Inc	Anticorps monoclonal anti-IL-1R1 thérapeutique
WO2004031777A1 (fr) *	2002-10-03	2004-04-15	Pfizer Products Inc.	Utilisation de gst-omega-2 en tant que cible therapeutique
ES2733577T3 (es)	2003-08-06	2019-12-02	Senomyx Inc	Nuevos aromas, modificadores del aroma, saborizantes, intensificadores del sabor, saborizantes umami o dulces y/o intensificadores y uso de los mismos
CN1934077B (zh) *	2004-03-23	2010-09-29	冬姆佩制药股份公司	2-苯基丙酸衍生物及含有它们的药物组合物
US20060045953A1 (en) *	2004-08-06	2006-03-02	Catherine Tachdjian	Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
BRPI0607006B1 (pt)	2005-02-04	2017-05-16	Senomyx Inc	compostos que compreendem funções orgânicas de hetero arilas ligadas e seus usos como novos modificadores, flavorizantes e promotores do sabor umami para composições comestíveis
WO2006090921A1 (fr) *	2005-02-28	2006-08-31	Eisai R & D Management Co., Ltd.	Effet d’inhibition d’un composé de sulfamide sur l’activation de lymphocytes
US7208526B2 (en) *	2005-05-20	2007-04-24	Hoffmann-La Roche Inc.	Styrylsulfonamides
AR055329A1 (es)	2005-06-15	2007-08-15	Senomyx Inc	Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
CN105152940A (zh)	2006-04-21	2015-12-16	西诺米克斯公司	含有高效鲜味调料的可食用组合物及其制备方法
EP1992344A1 (fr)	2007-05-18	2008-11-19	Institut Curie	P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
US7973051B2 (en) *	2007-11-30	2011-07-05	Hoffman-La Roche Inc.	Aminothiazoles as FBPase inhibitors for diabetes
US10154988B2 (en)	2012-11-14	2018-12-18	The Johns Hopkins University	Methods and compositions for treating schizophrenia
US10385040B2 (en)	2014-08-12	2019-08-20	Loyola University Of Chicago	Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same
LT3578547T (lt) *	2015-02-16	2021-08-25	The University Of Queensland	Sulfonilkarbamidai ir giminingi junginiai bei jų panaudojimas
US10688077B2 (en) *	2015-02-26	2020-06-23	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Inflammasome activation in myelodysplastic syndromes
FR3046933B1 (fr)	2016-01-25	2018-03-02	Galderma Research & Development	Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
SG11201806745RA (en)	2016-02-16	2018-09-27	Univ Queensland	Sulfonylureas and related compounds and use of same
MA44734A (fr) *	2016-04-18	2021-05-19	Novartis Ag	Composés et compositions destinés au traitement d'états associés à une activité de nlrp
EP3445757B1 (fr)	2016-04-18	2020-11-25	Novartis Inflammasome Research, Inc.	Composés et compositions pour traiter des états associés à une activité de nlrp
EP3272739A1 (fr) *	2016-07-20	2018-01-24	NodThera Limited	Derives de sulfonyluree et leur application en matiere de regulation de l'activite de l'interleukine-1
JP2020502064A (ja) *	2016-11-29	2020-01-23	エピザイム，インコーポレイティド	スルホン酸基を含むｋａｔ阻害剤としての化合物
EP3571187B1 (fr)	2017-01-23	2023-11-22	Genentech, Inc.	Composés chimiques comme inhibiteurs de l'activité interleukine-1
AU2017416068A1 (en) *	2017-05-24	2019-10-31	The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin	Novel compounds and uses
US11236045B2 (en)	2017-06-09	2022-02-01	Cadila Healthcare Limited	Substituted sulfoximine compounds
US11370776B2 (en)	2017-07-07	2022-06-28	Inflazome Limited	Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11465992B2 (en)	2017-07-07	2022-10-11	Inflazome Limited	Sulfonamide carboxamide compounds
IL271259B1 (en)	2017-07-24	2024-02-01	Novartis Inflammasome Res Inc	COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RELATED TO NLRP ACTIVITY
CA3071145A1 (fr)	2017-08-15	2019-02-21	Inflazome Limited	Nouveaux composes de sulfonamide carboxamide
EP3668842A1 (fr)	2017-08-15	2020-06-24	Inflazome Limited	Sulfonylurées et sulfonylthiourées en tant qu'inhibiteurs de nlrp3
US11518739B2 (en)	2017-08-15	2022-12-06	Inflazome Limited	Sulfonamide carboxamide compounds
JP2020531453A (ja)	2017-08-15	2020-11-05	インフレイゾームリミテッド	Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア
EP3668843A1 (fr)	2017-08-15	2020-06-24	Inflazome Limited	Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3
WO2019043610A1 (fr)	2017-08-31	2019-03-07	Cadila Healthcare Limited	Nouveaux dérivés de sulfonylurées substitués
EP3692020A1 (fr)	2017-10-03	2020-08-12	Inflazome Limited	Nouveaux composés
US11718631B2 (en)	2017-10-17	2023-08-08	Novartis Ag	Sulphonamides and compositions thereof for treating conditions associated with NLRP activity
GB201721185D0 (en)	2017-12-18	2018-01-31	Nodthera Ltd	Sulphonyl urea derivatives
CN108299256B (zh) *	2018-01-09	2019-09-10	武汉大学	一类2,3,4-三羟基苯磺酰胺衍生物及其制备方法和应用
US11884645B2 (en)	2018-03-02	2024-01-30	Inflazome Limited	Sulfonyl acetamides as NLRP3 inhibitors
US11834433B2 (en)	2018-03-02	2023-12-05	Inflazome Limited	Compounds
EP3759077A1 (fr)	2018-03-02	2021-01-06	Inflazome Limited	Nouveaux composés
WO2019166632A1 (fr)	2018-03-02	2019-09-06	Inflazome Limited	Nouveaux composés
JP2021529187A (ja)	2018-07-03	2021-10-28	ノバルティスアーゲー	Ｎｌｒｐモジュレータ
AU2019305095A1 (en)	2018-07-20	2020-12-17	F. Hoffmann-La Roche Ag	Sulfonylurea compounds as inhibitors of interleukin-1 activity
US20210236599A1 (en)	2018-08-13	2021-08-05	Iltoo Pharma	Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
CN113056451A (zh)	2018-10-24	2021-06-29	诺华股份有限公司	用于治疗与nlrp活性相关的病症的化合物和组合物
SG11202107680PA (en)	2019-01-14	2021-08-30	Cadila Healthcare Ltd	Novel substituted sulfonylurea derivatives
EP3986879A1 (fr)	2019-06-21	2022-04-27	AC Immune SA	1,2-thiazoles et 1,2 thiazines fusionnés qui agissent en tant que modulateurs de nl3p3
WO2021048809A1 (fr) *	2019-09-12	2021-03-18	Cadila Healthcare Limited	Nouveaux dérivés de type sulfoximine substitués
EP4166541A1 (fr) *	2020-06-11	2023-04-19	Medshine Discovery Inc.	Dérivé de diméthylsulfoximines
CN115768754A (zh)	2020-06-19	2023-03-07	Ac免疫有限公司	调节nlrp3炎症小体通路的二氢噁唑和硫脲或脲衍生物
WO2022022646A1 (fr) *	2020-07-29	2022-02-03	南京明德新药研发有限公司	Composé cyclique hétéroaromatique à cinq chaînons contenant du sélénium
WO2022051582A1 (fr)	2020-09-04	2022-03-10	NodThera Limited	Dérivés sulfamoyl-urée contenant une fraction alkyl-oxacycloalkyle et leurs utilisations
ES2948511A1 (es) *	2021-09-08	2023-09-13	Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa	Derivados de n-sulfonilureas y su uso terapeutico
WO2023098612A1 (fr) *	2021-12-03	2023-06-08	南京明德新药研发有限公司	Forme saline et forme cristalline de dérivé de diméthyl sulfoximine
WO2023118521A1 (fr)	2021-12-22	2023-06-29	Ac Immune Sa	Composés dérivés de dihydro-oxazol
WO2023156311A1 (fr) *	2022-02-15	2023-08-24	F. Hoffmann-La Roche Ag	Procédés pour la préparation de dérivés de 1,2,3,5,6,7-hexahydro-s-indacène
WO2023222565A1 (fr)	2022-05-16	2023-11-23	Institut National de la Santé et de la Recherche Médicale	Procédés d'évaluation de l'épuisement de cellules souches hématopoïétiques induites par une inflammation chronique
US20240034735A1 (en)	2022-07-14	2024-02-01	Ac Immune Sa	Novel compounds
WO2024023266A1 (fr)	2022-07-28	2024-02-01	Ac Immune Sa	Nouveaux composés

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4586950A (en) *	1982-05-31	1986-05-06	E. I. Du Pont De Nemours & Company	Novel phenyl-substituted sulfonamides
US4780125A (en) *	1982-09-01	1988-10-25	Ciba-Geigy Corporation	N-phenylsulfonyl-N'-triazinylureas
DE3927369A1 (de) *	1989-08-19	1991-02-21	Bayer Ag	Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe
US5064851A (en) *	1990-07-24	1991-11-12	Pfizer Inc.	3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
US5254589A (en) *	1991-10-15	1993-10-19	Warner-Lambert Company	Sulfonyl urea and carbamate ACAT inhibitors
DE4344957A1 (de) *	1993-12-30	1995-07-06	Hoechst Ag	Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen
CN1038679C (zh) *	1994-12-07	1998-06-10	南开大学	磺酰脲类化合物及其除草用途
HU226462B1 (en) *	1995-02-17	2008-12-29	Hoechst Ag	Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use
US6281240B1 (en) *	1997-04-10	2001-08-28	Eli Lilly And Company	Diarylsulfonylureas for use in treating secretory diarrhea

1997
- 1997-12-29 WO PCT/IB1997/001603 patent/WO1998032733A1/fr active IP Right Grant
- 1997-12-29 CA CA002279186A patent/CA2279186C/fr not_active Expired - Fee Related
- 1997-12-29 DK DK02020749T patent/DK1270565T3/da active
- 1997-12-29 PT PT97947201T patent/PT964849E/pt unknown
- 1997-12-29 AT AT97947201T patent/ATE242208T1/de not_active IP Right Cessation
- 1997-12-29 JP JP51868798A patent/JP3573757B2/ja not_active Expired - Fee Related
- 1997-12-29 IL IL13085597A patent/IL130855A0/xx unknown
- 1997-12-29 KR KR1019997006786A patent/KR100324058B1/ko not_active IP Right Cessation
- 1997-12-29 YU YU33799A patent/YU33799A/sh unknown
- 1997-12-29 DE DE69722663T patent/DE69722663T2/de not_active Expired - Fee Related
- 1997-12-29 NZ NZ336248A patent/NZ336248A/xx unknown
- 1997-12-29 EP EP97947201A patent/EP0964849B1/fr not_active Expired - Lifetime
- 1997-12-29 DE DE69729762T patent/DE69729762T2/de not_active Expired - Fee Related
- 1997-12-29 EA EA199900603A patent/EA001803B1/ru not_active IP Right Cessation
- 1997-12-29 BR BR9714328A patent/BR9714328A/pt not_active Application Discontinuation
- 1997-12-29 CN CN97181579A patent/CN1127479C/zh not_active Expired - Fee Related
- 1997-12-29 ES ES97947201T patent/ES2198598T3/es not_active Expired - Lifetime
- 1997-12-29 AU AU52340/98A patent/AU723895B2/en not_active Ceased
- 1997-12-29 CZ CZ19992575A patent/CZ293173B6/cs not_active IP Right Cessation
- 1997-12-29 PL PL97335052A patent/PL335052A1/xx unknown
- 1997-12-29 TR TR1999/01816T patent/TR199901816T2/xx unknown
- 1997-12-29 DK DK97947201T patent/DK0964849T3/da active
- 1997-12-29 US US09/341,782 patent/US6166064A/en not_active Expired - Fee Related
- 1997-12-29 ID IDW990764A patent/ID22223A/id unknown
- 1997-12-29 ES ES02020749T patent/ES2222426T3/es not_active Expired - Lifetime
- 1997-12-29 AT AT02020749T patent/ATE270285T1/de not_active IP Right Cessation
- 1997-12-29 PT PT02020749T patent/PT1270565E/pt unknown
- 1997-12-29 HU HU0000567A patent/HUP0000567A3/hu unknown
- 1997-12-29 SK SK982-99A patent/SK283679B6/sk unknown
1998
- 1998-01-16 PA PA19988444701A patent/PA8444701A1/es unknown
- 1998-01-20 UY UY24861A patent/UY24861A1/es unknown
- 1998-01-23 PE PE1998000051A patent/PE57898A1/es not_active Application Discontinuation
- 1998-01-26 TW TW087101087A patent/TW515788B/zh not_active IP Right Cessation
- 1998-01-27 HR HR980045A patent/HRP980045B1/xx not_active IP Right Cessation
- 1998-01-27 DZ DZ980017A patent/DZ2407A1/fr active
- 1998-01-27 AR ARP980100358A patent/AR011093A1/es not_active Application Discontinuation
- 1998-01-28 MA MA24947A patent/MA26468A1/fr unknown
- 1998-01-28 ZA ZA9800685A patent/ZA98685B/xx unknown
- 1998-01-28 TN TNTNSN98017A patent/TNSN98017A1/fr unknown
- 1998-01-29 CO CO98004326A patent/CO4920230A1/es unknown
- 1998-01-29 AP APAP/P/1998/001190A patent/AP929A/en active
1999
- 1999-06-29 IS IS5099A patent/IS5099A/is unknown
- 1999-07-22 BG BG103597A patent/BG103597A/bg unknown
- 1999-07-23 OA OA9900165A patent/OA11079A/en unknown
- 1999-07-28 NO NO19993658A patent/NO313279B1/no not_active IP Right Cessation
2000
- 2000-10-31 US US09/703,142 patent/US6433009B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR100324058B1 (ko)	2002-02-16
BG103597A (bg)	2000-02-29
UY24861A1 (es)	2000-09-29
WO1998032733A1 (fr)	1998-07-30
NZ336248A (en)	2000-10-27
AU723895B2 (en)	2000-09-07
JP2000511200A (ja)	2000-08-29
TNSN98017A1 (fr)	2005-03-15
MA26468A1 (fr)	2004-12-20
ES2198598T3 (es)	2004-02-01
CN1127479C (zh)	2003-11-12
AR011093A1 (es)	2000-08-02
AP9801190A0 (en)	1998-03-31
DE69722663T2 (de)	2004-04-29
EP0964849B1 (fr)	2003-06-04
HUP0000567A2 (hu)	2000-10-28
CA2279186A1 (fr)	1998-07-30
ZA98685B (en)	1999-07-29
EP0964849A1 (fr)	1999-12-22
US6166064A (en)	2000-12-26
HRP980045A2 (en)	1999-06-30
TR199901816T2 (xx)	1999-11-22
PL335052A1 (en)	2000-03-27
ES2222426T3 (es)	2005-02-01
PT1270565E (pt)	2004-09-30
TW515788B (en)	2003-01-01
CZ257599A3 (cs)	2000-09-13
ID22223A (id)	1999-09-16
DE69729762D1 (de)	2004-08-05
SK98299A3 (en)	2001-10-08
PT964849E (pt)	2003-08-29
NO313279B1 (no)	2002-09-09
DE69729762T2 (de)	2005-07-14
BR9714328A (pt)	2000-03-21
CA2279186C (fr)	2004-02-24
IS5099A (is)	1999-06-29
SK283679B6 (sk)	2003-11-04
PA8444701A1 (es)	2000-05-24
YU33799A (sh)	2002-03-18
CN1245490A (zh)	2000-02-23
HUP0000567A3 (en)	2002-10-28
EA001803B1 (ru)	2001-08-27
ATE270285T1 (de)	2004-07-15
NO993658L (no)	1999-09-28
OA11079A (en)	2002-03-14
KR20000070541A (ko)	2000-11-25
US6433009B1 (en)	2002-08-13
PE57898A1 (es)	1999-06-11
CO4920230A1 (es)	2000-05-29
ATE242208T1 (de)	2003-06-15
NO993658D0 (no)	1999-07-28
CZ293173B6 (cs)	2004-02-18
EA199900603A1 (ru)	2000-02-28
AU5234098A (en)	1998-08-18
DE69722663D1 (de)	2003-07-10
JP3573757B2 (ja)	2004-10-06
AP929A (en)	2001-01-18
HRP980045B1 (en)	2002-10-31
DK1270565T3 (da)	2004-10-04
IL130855A0 (en)	2001-01-28
DK0964849T3 (da)	2003-08-25

Publication	Publication Date	Title
DZ2407A1 (fr)	2003-01-04	Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2197A1 (fr)	2002-12-02	Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2300A1 (fr)	2002-12-25	Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr)	2002-12-25	Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2394A1 (fr)	2003-06-04	Dérivés de quinoléine et dérivés de quinazoline nouveax procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2581A1 (fr)	2003-02-22	Dérivés d'acides aryloxyarylsulfonylaminohydroxamiques procédé pour leur préparation et compositionspharmaceutiques les contenant.
CY2537B1 (fr)	2006-06-28	Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2303A1 (fr)	2002-12-28	Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2758A1 (fr)	2003-09-15	Dérivés bicycliques d0acide hydroxamique nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr)	2002-02-17	Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2666A1 (fr)	2003-03-22	Dérivés d'acide hydroxamique compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2360A1 (fr)	2002-12-28	Dérivés de pyrazole procédé pour leur préparation et compositions les contenant
DZ2773A1 (fr)	2003-12-01	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1957A1 (fr)	2002-02-17	Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2550A1 (fr)	2003-02-08	Dérivés d'azétidinylpropylpipéridine procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2777A1 (fr)	2003-12-01	Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2745A1 (fr)	2003-09-08	BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2414A1 (fr)	2003-01-04	2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2963A1 (fr)	2004-03-15	Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2634A1 (fr)	2003-03-08	Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant.
DZ2416A1 (fr)	2003-01-04	Dérivés d'acide arylsulfonylhydroxamique procédé pour leur préparation et compositions les contenant.
MA26659A1 (fr)	2004-12-20	Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2891A1 (fr)	2003-12-15	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2523A1 (fr)	2003-02-01	Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation.
DZ2621A1 (fr)	2003-03-08	AGonistes de prostaglandines nouveaux procédé pourleur préparation et compositions pharmaceutiques les contenant.